Related Experiment Videos
A novel grading scale for striatonigral degeneration (multiple system atrophy).
G K Wenning1, K Seppi, F Tison
1Department of Neurology, University of Innsbruck School of Medicine, Innsbruck, Austria.
Journal of Neural Transmission (Vienna, Austria : 1996)
|April 17, 2002
Summary
A new grading scale for striatonigral degeneration (SND) in multiple system atrophy (MSA) helps assess pathology severity. This scale correlates with parkinsonian disability and L-Dopa response, aiding clinical evaluation.
Area of Science:
- Neuropathology
- Neurodegenerative Diseases
Background:
- Striatonigral degeneration (SND) is a key pathology in multiple system atrophy (MSA), often linked to L-Dopa unresponsive parkinsonism.
- Standardized neuropathological evaluation is crucial for MSA research and clinical trials.
Observation:
- A novel semiquantitative grading scale for SND was developed based on 25 autopsy cases of MSA.
- The scale assesses neuronal loss, astrogliosis, and alpha-synuclein positive glial cytoplasmic inclusions (GCIs) in specific brain regions.
Findings:
- SND grades range from minimal changes (Grade I) to severe striatal pathology (Grade III).
- GCIs are more abundant in Grade II than Grade III.
- Preliminary data suggest milder parkinsonian disability and better L-Dopa responsiveness in Grades I and II compared to Grade III.
Implications:
- The proposed SND grading scale facilitates standardized neuropathological assessment in MSA.
- This scale may aid in stratifying patients for clinical trials and understanding disease progression.
- Further validation and potential subdivision of the scale are warranted.